Latest News

Latest results with ctDNA, single-cell RNA sequencing, and the microbiome.

The 48 Yale Cancer Center presentations will include phase II trial results for a cancer vaccine in combination with an immunotherapy drug, a new tool to predict the risk of recurrence of hormone receptor-positive, HER2-negative breast cancer, and the factors affecting sexual function of young women with breast cancer.

Roy S. Herbst, MD, PhD, deputy director and chief of medical oncology at Yale Cancer Center, New Haven, Connecticut, emphasized the need for further research to refine the utility of ctDNA analysis in guiding treatment decisions, especially in advanced disease. He expressed reservations about the use of chemotherapy in combination with targeted therapy, citing its associated side effects and inconvenience for patients. “We need large phase 4 studies of patients on these drugs to figure out the right timing and the right test,” Dr Herbst said. “It’ll happen in due time, but it’s not happening yet.”

“Many, however, have already advised people to consider starting screening mammograms at age 40,” said Maryam Lustberg, director of the Center for Breast Cancer at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut.

James Hansen, MD, MS, participates in a Q&A in honor of Brain Tumor Awareness Month.

Smilow Shares with Primary Care: Breast Cancer

Amos S. Espinosa, a PhD Candidate in Experimental Pathology, was recently named a winner of the American Society of Hematology's Minority Hematology Graduate Award.

In the body, certain enzymes are key to cell communication and their dysfunction can lead to cancer. A new study begins to uncover how they signal and when.

Bohdan Pomahac, MD, has performed the most face transplants in the world.